@precisionmedcin

Created to inform those interested in seeing Precision Medicine become a reality with the latest news, research, commentary, and funding.

Joined February 2015
  • Tweets3.1K
  • Following250
  • Followers2.7K
29Media
newsnetwork.mayoclinic.org/d…

Mayo Clinic, Thermo Fisher launch Precure

Mayo Clinic and Thermo Fisher Scientific launch Precure, combining multi-omics and clinical data to study biological signs of disease before symptoms.

newsnetwork.mayoclinic.org
49
Precision Medicine retweeted
nature
@NatureAug 31
Nature research paper: A binding-to-release strategy for targeted anticancer drug delivery go.nature.com/46l6Bg2

A binding-to-release strategy for targeted anticancer drug delivery

Nature - A binding-to-release drug conjugate strategy enables targeted payload release without cellular internalization, improving tumour specificity, efficacy and expanding therapeutic targets...

nature.com
6
50
3
295
61,360
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com/2026/08/19/mrna…

Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

statnews.com
70
Precision Medicine retweeted
Nature Medicine
@NatureMedicineAug 17
Research highlights morphological changes in 40 tissue types linked to aging. By integrating these with blood transcriptomic data, we develop aging clocks that reflect tissue integrity and organ health. Learn more: dlvr.it/TV3RL0

Histological aging signatures for monitoring tissue-specific aging and disease

Nature Medicine - Whole-slide histopathological images from 40 tissue types reveal morphological changes associated with aging, which, when paired with transcriptomic data from blood, are used to...

nature.com
22
53
12,369
Precision Medicine retweeted
NIH
@NIHJul 23
📢 New Funding Opportunity from the NIH Common Fund’s PRIMED-AI program: Researchers are invited to apply for support to help move validated AI-powered clinical decision support tools from prototype to real-world clinical implementation. 📅 Applications due: October 19, 2026 ➡️ Learn more: go.nih.gov/4Nj8TLv
4
9
1
44
16,939
Precision Medicine retweeted
Parse Biosciences@ParseBioJul 22
Applications are now open for the Parse Single Cell Immunology Grant! Watch our informational session for all of the grant details and apply here: parse.bio/4vOMqS7 Submissions close on August 10th at 11:59 PM Pacific.
1
1
102
All of Us tests a new approach to collect real-world data for research statnews.com/2026/06/30/nih-… via @statnews The days of hoarding patient data are rapidly ending, thanks to #HIE (and #EHR), and @AllofUsResearch is putting newly obtained genotype-phenotype information to good use in #PM101.

All of Us tests a new approach to collect real-world data for research

The NIH All of Us Research Program has secured thousands of electronic medical records through an innovative use of patient data-sharing networks

statnews.com
1
1
150
Precision Medicine retweeted
Samuel Hume
@DrSamuelBHumeMay 31
One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore
103
1,484
248
9,539
2,061,185
#ASCO : Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival - BioSpace biospace.com/drug-developmen…

ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help...

biospace.com
1
63
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise clinicaltrialsarena.com/news…

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

Read about Asco26 Cancer Vaccines And At Home Injectable Drugs Continue To Show Promise. Read the coverage from Clinical Trials Arena.

clinicaltrialsarena.com
38
Precision Medicine retweeted
HHMI
@hhmi_scienceMay 9
A new gene-editing strategy from #HHMIInvestigator Michel Nussenzweig's lab could teach the immune system to produce its own therapeutic antibodies. Successful so far in mice, the approach may lead to treatments for HIV, cancer, metabolic disease, & more: bit.ly/4tkQvfo
HHMI Investigator Michel Nussenweig in the lab

ALT HHMI Investigator Michel Nussenweig in the lab

1
32
1
136
13,936
Precision Medicine retweeted
NIH
@NIHApr 13
🚨NEWS: New bite-sized CRISPR molecule may open doors for therapeutic genome editing. Read the full story ➡️ bit.ly/4dK5FXI

NIH-funded breakthrough shrinks CRISPR for precision delivery in the body

Smaller gene-editing system could expand treatment options for cancer, ALS and other diseases.

nih.gov
14
35
7
96
25,800
Precision Medicine retweeted
NIH
@NIHMar 23
Join us for the last public webinar on the NIH-Wide Strategic Plan! NIH leadership will share the framework and answer questions live. Registration is required—submit questions when you sign up or during the webinar. Register here: bit.ly/3Px9fdj.
Promotional image for NIH Strategic Plan Webinars for fiscal years 2027-2031. Includes a register button and mentions leadership discussing the framework for the next NIH-wide Strategic Plan. Date: April 8, 2026. Features NIH logo.

ALT Promotional image for NIH Strategic Plan Webinars for fiscal years 2027-2031. Includes a register button and mentions leadership discussing the framework for the next NIH-wide Strategic Plan. Date: April 8, 2026. Features NIH logo.

2
22
1
38
10,698
If you haven’t watched the Technologies Transforming #PrecisionMedicine documentary yet, it’s well worth your time. 🎬 bit.ly/3Z1jdoY Featuring field pioneers in precision medicine, it explores the core technologies shaping personalized healthcare, from #NGS and #flowcytometry to #liquidbiopsy, #organoids, #spatial biology, and #antibodydiscovery, and how they work together across the precision medicine workflow.
1
4
148
Big news in the #singlecell world ⁦@ParseBio⁩ ⁦@QIAGEN⁩ parsebiosciences.com/news/pa…

Parse Biosciences is joining QIAGEN!Parse Biosciences plans to join QIAGEN as a part of its Sample...

Parse Biosciences plans to join QIAGEN as a part of its Sample Technologies group.

parsebiosciences.com
1
46
Precision Medicine retweeted
Eric Topol
@EricTopol1 Nov 2025
Three basic science studies this week with potential big impact for cancer treatment (and beyond) 1. Determining why BRCA2 cancers are resistant to current therapies @ScienceMagazine science.org/doi/10.1126/scie…
5
121
6
451
81,677
Precision Medicine retweeted
Parse Biosciences@ParseBio20 Oct 2025
📣Evercode Single Cell Grant Available! parse.bio/49cdPFG Submit your abstract for our single cell grant by Tuesday, October 28th at 11:59 PM Pacific for a chance to take your work further with the Evercode Technology.
2
3
277
Sequencing Strategies for Understanding and Diagnosing Disease biocompare.com/Editorial-Art…

Sequencing Strategies for Understanding and Diagnosing Disease

No single method is ideal for every application, but each has benefits.

biocompare.com
41
Will be following this exciting development. #CRISPR
nature
@Nature7 Sep 2025
In a medical first, researchers report that they have implanted CRISPR-edited pancreas cells into a person with type 1 diabetes go.nature.com/4p8v7Jz

Hope for diabetes: CRISPR-edited cells pump out insulin in a person — and evade immune detection

Nature - Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.

nature.com
2
118
Precision Medicine retweeted
Targeted Oncology@TargetedOnc27 Aug 2025
A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation. Learn more about the clinical implications here: hubs.li/Q03FQQtr0

Novel Assay Identifies Low-Risk Patients With ER+ Early Breast Cancer | Targeted Oncology -...

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation.

targetedonc.com
2
1
315
Load more